Search

Micheline Lisa Markey

from Atherton, CA
Age ~66
Get Report
Also known as:
Micheline L Markey
Phone and address:
30 Middlegate St, Menlo Park, CA 94027
Related to:
Marcia Elizabeth Markey, 65Frank R MarkeyMichael F MarkeySteven MarkeyDorothy M Markey
Connected to:
Alan V Markey, 36Amanda J Markey, 37Anna M Markey, 95Bernadette Markey, 53Bernard O Markey, 101Britt L Markey, 38Callie E Markey, 38Colleen M Markey, 62Deanna Markey, 52Detra S Markey, 66

Micheline Markey Phones & Addresses

  • 30 Middlegate St, Atherton, CA 94027
  • 160 Selby Ln, Atherton, CA 94027
  • Menlo Park, CA
  • 738 Chestnut St, Santa Cruz, CA 95060
  • Birmingham, MI
  • San Jose, CA
  • San Mateo, CA

Work

Company: Covidien Apr 2013 to Jan 2015 Position: Chemist fellow

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of California, Santa Cruz 1991 to 1997 Specialities: Chemistry

Skills

Drug Delivery • Analytical Chemistry • Formulation • Medical Devices • Fda • Technology Transfer • Protein Chemistry • R&D • Characterization • Ftir • Assay Development • Nmr • Analysis • Clinical Trials • Polymers • Spectroscopy • Hplc • Design Control • V&V • Purification • Protein Expression • Chromatography • In Vitro • Differential Scanning Calorimetry • In Vivo • Glp • Biomaterials • U.s. Food and Drug Administration • Lifesciences • Research and Development • Analytical Method Development • Controlled • Drug Product • High Performance Liquid Chromatography • Life Sciences • Formulation Development • Targeted Controlled Drug Release

Languages

English

Industries

Medical Devices

Resumes

Resumes

Micheline Markey Photo 1

Cmc Analytical Fellow

View page
Location:
30 Middlegate St, Atherton, CA 94027
Industry:
Medical Devices
Work:
Covidien Apr 2013 - Jan 2015
Chemist Fellow
Chrono Therapeutics Apr 2013 - Jan 2015
Research
Cv Ingenuity Jul 2012 - Apr 2013
Senior Director Analytical Development
Independent Consulting Jul 2012 - Apr 2013
Principal Scientist
Johnson & Johnson 2007 - 2011
Principal Scientist
Education:
University of California, Santa Cruz 1991 - 1997
Doctorates, Doctor of Philosophy, Chemistry Wayne State University
Bachelors, Bachelor of Science, Chemical Engineering
Skills:
Drug Delivery
Analytical Chemistry
Formulation
Medical Devices
Fda
Technology Transfer
Protein Chemistry
R&D
Characterization
Ftir
Assay Development
Nmr
Analysis
Clinical Trials
Polymers
Spectroscopy
Hplc
Design Control
V&V
Purification
Protein Expression
Chromatography
In Vitro
Differential Scanning Calorimetry
In Vivo
Glp
Biomaterials
U.s. Food and Drug Administration
Lifesciences
Research and Development
Analytical Method Development
Controlled
Drug Product
High Performance Liquid Chromatography
Life Sciences
Formulation Development
Targeted Controlled Drug Release
Languages:
English

Publications

Us Patents

Extending The Duration Of Drug Release Within The Stomach During The Fed Mode

View page
US Patent:
6635280, Oct 21, 2003
Filed:
Nov 6, 2001
Appl. No.:
10/045823
Inventors:
John W. Shell - Hillsborough CA
Micheline Markey - Santa Cruz CA
Assignee:
DepoMed, Inc. - Menlo Park CA
International Classification:
A61K 926
US Classification:
424469, 424464, 424468, 424488, 424486, 424487
Abstract:
Drugs are formulated as unit oral dosage forms by incorporating them into polymeric matrices comprised of hydrophilic polymers that swell upon imbibition of water to a size that is large enough to promote retention of the dosage form in the stomach during the fed mode. The oral formulation is designed for gastric retention and controlled delivery of an incorporated drug into the gastric cavity, and thus administered, the drug is released from the matrix into the gastric fluid by solution diffusion. The swollen polymeric matrix, having achieved sufficient size, remains in the gastric cavity for several hours if administered while the patient is in the fed mode, and remains intact long enough for substantially all of the drug to be released before substantial dissolution of the matrix occurs. The swelling matrix lowers the accessibility of the gastric fluid to the drug and thereby reduces the drug release rate. This process, together with diffusion retardation by selection of specific polymers, polymer molecular weights, and other variables, results in a sustained and controlled delivery rate of the drug to the gastric cavity.

Pharmacological Inducement Of The Fed Mode For Enhanced Drug Administration To The Stomach

View page
US Patent:
7405238, Jul 29, 2008
Filed:
Sep 4, 2002
Appl. No.:
10/235076
Inventors:
Micheline Markey - Santa Cruz CA, US
John W. Shell - Hillsborough CA, US
Bret Berner - El Granada CA, US
Assignee:
Depomed Inc. - Menlo Park CA
International Classification:
A61K 31/21
A61K 47/00
US Classification:
514513, 424439
Abstract:
Drugs intended for absorption in the stomach or upper intestinal tract are administered in oral drug delivery systems in conjunction with any of various substances that have been discovered to function as potent agents for inducing the fed mode. By inducing the onset of the fed mode, these agents cause the stomach to prolong its retention of the drug delivery system, which is either large enough to be retained in the stomach during the fed mode or swells or expands to such a size upon ingestion. The fed mode inducing agents include the following compounds and their salts: glycine and glycylglycine, xylitol and related sugar alcohols, sodium and other metal docusates, β-casomorphins, α-lipoic acid and similarly structured acids, 2,2-diaryl-4-(4′-aryl-4′-hydroxypipendino)butyramides, arginine, Trp-Trp, alkylpyridinium halides, dihydroxybenzoic acids, and potent sweeteners such as aspartame, aspartic acid, acesulfame, and stevioside.

Extending The Duration Of Drug Release Within The Stomach During The Fed Mode

View page
US Patent:
20010018070, Aug 30, 2001
Filed:
Mar 29, 1999
Appl. No.:
09/282233
Inventors:
JOHN W. SHELL - HILLSBOROUGH CA, US
MICHELINE MARKEY - SANTA CRUZ CA, US
International Classification:
A61K009/20
A61K009/26
A61K009/14
US Classification:
424/469000, 424/464000, 424/465000
Abstract:
Drugs are formulated as unit oral dosage forms by incorporating them into polymeric matrices comprised of hydrophilic polymers that swell upon imbibition of water to a size that is large enough to promote retention of the dosage form in the stomach during the fed mode. The oral formulation is designed for gastric retention and controlled delivery of an incorporated drug into the gastric cavity, and thus administered, the drug is released from the matrix into the gastric fluid by solution diffusion. The swollen polymeric matrix, having achieved sufficient size, remains in the gastric cavity for several hours if administered while the patient is in the fed mode, and remains intact long enough for substantially all of the drug to be released before substantial dissolution of the matrix occurs. The swelling matrix lowers the accessibility of the gastric fluid to the drug and thereby reduces the drug release rate. This process, together with diffusion retardation by selection of specific polymers, polymer molecular weights, and other variables, results in a sustained and controlled delivery rate of the drug to the gastric cavity.

Extending The Duration Of Drug Release Within The Stomach During The Fed Mode

View page
US Patent:
20020051820, May 2, 2002
Filed:
Nov 20, 2001
Appl. No.:
09/990061
Inventors:
John Shell - Hillsborough CA, US
Micheline Markey - Santa Cruz CA, US
Assignee:
DepoMed, Inc. - Menlo Park CA
International Classification:
A61K009/26
A61K009/14
US Classification:
424/484000, 424/486000, 424/487000, 424/488000
Abstract:
Drugs are formulated as unit oral dosage forms by incorporating them into polymeric matrices comprised of hydrophilic polymers that swell upon imbibition of water to a size that is large enough to promote retention of the dosage form in the stomach during the fed mode. The oral formulation is designed for gastric retention and controlled delivery of an incorporated drug into the gastric cavity, and thus administered, the drug is released from the matrix into the gastric fluid by solution diffusion. The swollen polymeric matrix, having achieved sufficient size, remains in the gastric cavity for several hours if administered while the patient is in the fed mode, and remains intact long enough for substantially all of the drug to be released before substantial dissolution of the matrix occurs. The swelling matrix lowers the accessibility of the gastric fluid to the drug and thereby reduces the drug release rate. This process, together with diffusion retardation by selection of specific polymers, polymer molecular weights, and other variables, results in a sustained and controlled delivery rate of the drug to the gastric cavity.

Expandable Medical Device For Treating Cardiac Arrhythmias

View page
US Patent:
20040249443, Dec 9, 2004
Filed:
Jul 1, 2004
Appl. No.:
10/883129
Inventors:
John Shanley - Redwood City CA, US
Micheline Markey - Santa Cruz CA, US
International Classification:
A61F002/06
US Classification:
623/001150, 623/001420, 606/108000
Abstract:
An expandable medical device has a plurality of elongated struts joined together to form a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter. At least one of the plurality of struts includes at least one opening extending at least partially through a thickness of said strut. A beneficial agent is loaded into the opening within the strut in layers to achieve desired temporal release kinetics of the agent. The beneficial agent can be a chemically ablative agent use to create a lesion to treat atrial fibrillation. A wide variety of delivery profiles can be achieved including zero order, pulsatile, increasing, decrease, sinusoidal, and other delivery profiles.

Expandable Medical Device With Beneficial Agent Matrix Formed By A Multi Solvent System

View page
US Patent:
20050100577, May 12, 2005
Filed:
Apr 22, 2004
Appl. No.:
10/830566
Inventors:
Theodore Parker - Danville CA, US
John Shanley - Redwood City CA, US
Micheline Markey - Santa Cruz CA, US
International Classification:
A61K038/28
A61K031/7076
A61K031/445
A61F002/00
A61K009/22
US Classification:
424423000, 604890100, 514003000, 514046000
Abstract:
A multi solvent drug delivery matrix formation method is used to place layers into a reservoir in a stent in a stepwise manner to achieve extended delivery of water soluble, sensitive, or difficult to deliver drugs. The multi solvent matrix formation method allows the formation of a drug reservoir with a layered morphology in which the mixing between layers is limited to allow the different layers to perform different functions in controlling drug delivery. A stent having a drug delivery matrix includes a first beneficial agent layer affixed to the stent by depositing a first solution of a first polymer and a first solvent, and a second beneficial agent layer affixed to the first beneficial agent layer by depositing a second solution of a second polymer and a second solvent. The second solvent is selected so that the first polymer is substantially insoluble in the second solvent to prevent degradation of the first polymer during deposition of the second polymer. A therapeutic agent is provided in the first beneficial agent layer or the second beneficial agent layer to form a drug delivery matrix.

Implantable Medical Device With Openings For Delivery Of Beneficial Agents With Combination Release Kinetics

View page
US Patent:
20060229713, Oct 12, 2006
Filed:
Jun 6, 2006
Appl. No.:
11/448319
Inventors:
John Shanley - Redwood City CA, US
Theodore Parker - Danville CA, US
Thai Nguyen - Santa Clara CA, US
Micheline Markey - Atherton CA, US
Gary Steese-Bradley - San Jose CA, US
Assignee:
Conor Medsystems, Inc. - Menlo Park CA
International Classification:
A61F 2/06
US Classification:
623001420
Abstract:
A method and system for delivering drug includes a first set of holes filled with a first formulation of the drug and a second set of holes filled with a second formulation of the same drug. This dual formulation or dual release kinetic system allows the creation of specifically tailored release kinetics by summation of multiple release kinetics.

System And Method For Local Delivery Of Antithrombotics

View page
US Patent:
20070112414, May 17, 2007
Filed:
Sep 5, 2006
Appl. No.:
11/516054
Inventors:
Theodore Parker - Danville CA, US
Frank Litvack - Los Angeles CA, US
Micheline Lisa Markey - Atherton CA, US
Assignee:
Conor Medsystems, Inc. - Menlo Park CA
International Classification:
A61F 2/06
US Classification:
623001150, 623001420
Abstract:
Dipyridamole is an antithrombotic agent which also promotes the growth of endothelial cells. An endothelial cell lining within a stent is necessary for complete healing on the interior of the stent. A dual drug dipyridamole stent includes a first drug formulation of dipyridamole and polymer arranged in a first set of holes in the stent for primarily luminal delivery and a second drug formulation of an antirestenotic agent and polymer arranged in a second set of holes in the stent for primarily mural delivery. The delivery of dipyridamole luminally into the blood stream can involve a two phase release with the first phase being a burst to prevent initial clotting or thrombus formation followed by a second phase with a much slower and more sustained release to reduce thrombogenicity and promote the growth of the endothelial cell lining.
Control profile
Micheline Lisa Markey from Atherton, CA, age ~66 Get Report